Dr Lal Pathlabs Ltd

Dr Lal Pathlabs | 539524

Market Closed

₹1,904.40

₹30.18 (-1.56%)

As on 02/09/26, 1:10 AM

Market Cap31,965.13 CR

Current Price₹1,904.4

High / Low₹1,988.9 / 1,272.6

PE Ratio43.61

Book Value₹149.69

Dividend Yield1.56%

ROCE27.45%

ROE22.06%

Face Value₹2.00

Current Vol.4,68,711

Average Vol.---

ISININE600L01024

PB Ratio8.78

Debt to Equity0.08

Net Profit Margin18.45

Operating Margin30.9

LALPATHLAB - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹1,934.6₹1,934.8

₹1,904.4

Previous CloseToday's Open

₹1,272.6₹1,988.9

₹1,904.4

52W Low52W High

₹1,934.8Today's Open

₹1,934.6Previous Close

4,68,711Volume

₹1,272.652W Low

₹1,988.952W High

Ratios

No data available

About Company

Lal PathLabs Limited was incorporated as a Private Limited Company with the name Dr
Lal PathLabs Private Limited', on February 14, 1995 at Delhi
The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company
The Company converted into a Public Limited Company and name of the Company was changed to Dr
Lal PathLabs Limited' vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015
Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres
Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations
The Company has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 371 other clinical laboratories, 5,102 patient service centers and 10,938 pickup points as of 31 March 2023
Its customers include individual patients, hospitals and other healthcare providers and corporate customers
Apart from these, the catalogue of services includes 481 test panels, 2763 pathology tests and 1947 radiology and cardiology tests

Ethics: Dr Lal Pathlabs Ltd is flagged for

Animal Cruelty

The company engages directly in some form of animal cruelty through its business.

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI62.50

SMA 201918.22

SMA 501800.32

SMA 1001671.75

SMA 2001551.08

SMA 101910.91

MACD_12_26_Days33.98

EMA10Day1919.48

EMA20Day1898.88

EMA50Day1814.56

MACD_12_26_9_Days-6.08

EMA100Day1712.33

EMA200Day1621.13

Pivot Points

Volume Analysis

Delivery

Total Volume

Growth Rate

Revenue Growth12.25%

ROE21.78%

EBITDA Margin30.90%

All figures in ₹ Crores

Indicators	2026	2025	2024	2023	2022
Revenue	2,762.91	2,461.40	2,226.64	2,016.88	2,087.41
Interest	22.80	22.31	29.36	37.53	30.18
Expenses	1,980.40	1,765.80	1,617.40	1,527.05	1,526.68
Financing Profit	883.78	789.03	678.41	531.55	613.27
Financing Margin %	32%	32%	30%	26%	29%
Other Income	101.27	93.43	69.17	41.72	52.55
Depreciation	161.80	141.92	143.60	150.19	108.11
Profit before tax	669.09	624.80	505.45	343.83	474.98
Tax %	24%	21%	28%	30%	26%
Net Profit	509.75	492.25	362.29	241.08	350.29
EPS in Rs	30.24	29.24	43.05	28.82	41.70

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
GOLDMAN SACHS BANK EUROPE SE - ODI	20 Oct ‘25	Purchase	33,414	₹3,160	51.05%
GOLDMAN SACHS (SINGAPORE) PTE - ODI	20 Oct ‘25	Sell	33,414	₹3,160	51.05%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Oct ‘22	Sell	45,068	₹2,518.75	16.76%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Oct ‘22	Purchase	45,068	₹2,518.75	16.76%
ISHARES INDIA SC MAURITIUS COMPANY	03 Oct ‘22	Sell	8,417	₹2,518.75	3.13%
ISHARES MSCI INDIA SMALL-CAP ETF	03 Oct ‘22	Purchase	8,417	₹2,518.75	3.13%

News

📊

No Information Available

No news available for this company.

Record Date

Corporate Action

Information

Announcement Day

30 Jul 2026

Interim Dividend (₹5)

Approved declaration of Interim Dividend of INR 5/- per equity share (@ 50% on a face value of INR 10/- each) for the FY 2026-27

24 Jul 2026

25 Jul 2026

AGM

30 Apr 2026

26 Jun 2026

Final Dividend (₹4)

Recommendation of final dividend of INR 4/- per equity share (@ 40% on a face value of INR 10/- each) for the financial year ended March 31, 2026, subject to approval of the Members of the Company at ensuing Annual General Meeting ('AGM'). The record date for the purpose of payment of final dividend shall be June 26, 2026

30 Apr 2026

05 Feb 2026

Interim 3 Dividend (₹3.5)

Declaration of 3rd Interim Dividend of INR 3.5/- per equity share (@35% on a face value of INR 10/- each) for the financial year 2025-26. The Record Date for the purpose of payment of Interim Dividend shall be February 5, 2026.

30 Jan 2026

19 Dec 2025

Bonus Issue (1:1)

1:1 Bounus Issue of Equity Shares

12 Dec 2025

07 Nov 2025

Interim 2 Dividend (₹7)

Declaration of 2nd Interim Dividend of INR 7/- per equity share (@ 70% on a face value of INR 10/- each) for the financial year 2025-26. The record date for the purpose of payment of Interim Dividend shall be November 7, 2025.

31 Oct 2025

06 Aug 2025

Interim Dividend (₹6)

Decleration of Interim Dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year 2025-26. The record date for the purpose of payment of Interim Dividend shall be August 06, 2025

31 Jul 2025

28 Jun 2025

AGM

25 Apr 2025

06 Jun 2025

Final Dividend (₹6)

Recommendation of final dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year ended March 31, 2025, subject to approval of the Members of the Company at ensuing Annual General Meeting ('AGM'). The record date for the purpose of payment of final dividend shall be June 06, 2025. The Final Dividend will be dispatched/ credited within 30 days of the approval by the Members.

25 Apr 2025

06 Feb 2025

EGM

06 Feb 2025

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
1,904	31,950	57	13	44	0	18.45%
8,763	1,25,998	60	13	42	1	7.94%
747	98,259	105	6	59	1	8.87%
1,007	98,009	65	9	50	0	17.23%
911	68,769	64	7	45	0	11.20%
758	66,090	170	14	100	0	7.26%
1,938	39,605	46	9	29	1	10.21%
1,457	39,163	68	10	48	0	12.56%
759	31,878	153	9	59	2	6.20%
1,755	17,790	56	6	40	0	14.05%

Showing 10 of 70 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in just 5 minutes*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

EPLEPL Ltd
₹240.35-21.71 (-8.28%)

Group Stocks

Adani Stocks

Tata Group Stocks

Frequently Asked Questions

What is Share Price of Dr Lal Pathlabs Ltd?

The current share price of Dr Lal Pathlabs Ltd (Dr Lal Pathlabs) is ₹1904.40. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Dr Lal Pathlabs Ltd?

The Price-to-Earnings (P/E) ratio of Dr Lal Pathlabs Ltd is 1904.40. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Dr Lal Pathlabs Ltd?

Dr Lal Pathlabs Ltd has a 52-week high of ₹1988.90 and a 52-week low of ₹1272.60. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Dr Lal Pathlabs Ltd?

Dr Lal Pathlabs Ltd offers a dividend yield of 1.06%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Dr Lal Pathlabs Ltd?

The Earnings Per Share (EPS) of Dr Lal Pathlabs Ltd is ₹33.51. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Dr Lal Pathlabs Ltd?

Dr Lal Pathlabs Ltd has a Return on Equity (ROE) of 22.06%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds. Play Video